10:11 AM EST - Microbix Biosystems Inc. : And EMQN CIC, a global supplier of laboratory external quality assessment schemes for human genomic testing, announce the go-live of a program to support the accurate identification of patients who carry a gene-variant associated with increased susceptibility to hearing loss following treatment with a widely-used class of antibiotics. Microbix Biosystems Inc.
shares T.MBX are trading unchanged at $0.35.
